Search for a command to run...
A Stanford-trained scientist explores the cutting-edge world of magnetogenetics, developing a new technology at Nonfiction Labs that could revolutionize cancer therapies by using magnets to precisely control drug targeting in the body.
A deep dive into the booming underground market of Chinese peptides, exploring their growing popularity among tech workers in San Francisco, their unregulated supply chain, and the cultural trends driving their experimental use.
Dr. Martin Picard explores how mitochondria are not just energy producers, but dynamic organelles that transform energy and translate our behaviors, mindset, and experiences into cellular vitality, challenging linear views of aging and offering insights into optimizing health through understanding energy flow.
Dr. Glen Jeffery discusses how long wavelength light can improve mitochondrial function, metabolism, and cellular health, while warning about the potential harmful effects of short wavelength LED lighting on biological systems.
A deep dive into testosterone's role in shaping male development, exploring how prenatal hormonal surges drive sex-based behavioral differences, aggression patterns, and the complex interplay between biology, evolution, and culture.
Kent Heckenlively explores the current state of UFO and alien claims, examining whistleblower testimonies, congressional hearings, and intriguing evidence like Peruvian mummies while maintaining a skeptical yet open-minded approach to the possibility of extraterrestrial contact.
An interview with Lada Nuzhna, founder of General Control, exploring her journey in biotech, the challenges of developing aging therapies, and her mission to engineer epigenetic medicines that could potentially extend human lifespan.
Two venture capitalists explore the brutal economics of biotech, revealing why the industry is struggling despite scientific advances, and how new modalities, AI, and a focus on invention could revive innovation in drug development.
Dave Ricks, CEO of Eli Lilly, discusses the company's groundbreaking GLP-1 drugs, their potential beyond weight loss, the complexities of drug development and pricing, and how Eli Lilly is innovating in pharmaceutical research and direct-to-consumer healthcare.